Diamedica Inc.

Monthly archive

Press Releases - 2011

DiaMedica’s DM-204 for Type 2 Diabetes Successfully Humanized

Posted by Anonymous on Dec, 19 2011

 WINNIPEG, Manitoba, Canada – December 19, 2011 – DiaMedica Inc. (TSX-V: DMA) is pleased to announce the successful humanization of its monoclonal antibody (mAb), DM-204, for Type 2 diabetes and diabetic related complications of hypertension (high blood pressure) and cholesterol.

DiaMedica’s DM-199 for Type 1 Diabetes Significantly Delays Autoimmune Attack and Demonstrates a Dramatic Increase in C-Peptide Levels

Posted by admin on Dec, 5 2011

WINNIPEG, Manitoba, Canada – December 5th, 2011 – DiaMedica Inc. (TSX-V: DMA) is pleased to announce new compelling Type 1 diabetes data. An in vivo study with the chronic administration of DM-199 significantly delayed the autoimmune attack, preserved beta cell mass and demonstrated a 12-fold increase in circulating C-peptide levels in the non-obese diabetic (NOD) animal model.

DiaMedica’s DM-204 for Type 2 Diabetes Significantly Lowers Blood Glucose, Blood Pressure and Cholesterol Levels

Posted by admin on Dec, 1 2011

WINNIPEG, Manitoba, Canada – December 1st, 2011 – DiaMedica Inc. (TSX-V: DMA) is pleased to announce the presentation of new compelling Type 2 diabetes data from studies of DM-204 at the Windhover Therapeutic Area Partnership Conference in Boston, MA, USA.

In an independently conducted study, chronic administration of DM-204 prevented disease progression within an in vivo Type 2 diabetes model. Treatment with DM-204 resulted in statistically significant lower mean differences compared to untreated animals after 21 days for the following parameters:

DiaMedica Announces Formation of Development Advisory Group for its DM-199 and DM-204 Diabetes Products

Posted by Anonymous on Nov, 29 2011

WINNIPEG, Manitoba, Canada - November 29, 2011 - DiaMedica Inc. (TSX-V: DMA) a biopharmaceutical company focused on the development of novel treatments for Type 1 and Type 2 diabetes announces the formation of a development advisory group for its DM-199 and DM-204 products for the treatment of Type 1 and Type 2 diabetes. The advisory group consists of Dr. Joy Cavagnaro, Dr. Patrick Gearing, and Mr. Larry Johnson; industry experts in the areas of pharmacology and toxicology, manufacturing and regulatory affairs.

Dr. Paul Burn to join DiaMedica’s Scientific Advisory Board

Posted by Anonymous on Oct, 27 2011

WINNIPEG, Manitoba, Canada – October 27, 2011 – DiaMedica Inc. (TSX-V: DMA) a biopharmaceutical company focused on the development of novel treatments for Type 1 and Type 2 diabetes announces the appointment of Dr. Paul Burn to DiaMedica’s Scientific Advisory Board. Dr. Burn currently serves as the Broin Chair and Director for The Sanford Project, an emerging translational research center focused on identifying and delivering a cure for Type 1 diabetes.

DiaMedica’s DM-199 and DM-204 both Named to Windhover’s “2011 Top 10 Cardiovascular/Metabolic Projects to Watch”

Posted by Anonymous on Oct, 12 2011

WINNIPEG, Manitoba, Canada – October 12, 2011 – DiaMedica Inc. (TSX-V: DMA) a biopharmaceutical company focused on the development of novel treatments for diabetes, announces that its DM-199 and DM-204 products have been selected by Windhover Information as one of the 2011 Top 10 Most Interesting Cardiovascular/Metabolic Projects to Watch for strategic partnerships.

DiaMedica Named 2011 Emerging Company of the Year by Life Science Association of Manitoba

Posted by Anonymous on Oct, 6 2011

WINNIPEG, Manitoba, Canada – October 6, 2011 – DiaMedica Inc. (TSX-V: DMA) a biopharmaceutical company focused on the development of novel treatments for diabetes announces that the Company has received the 2011 Emerging Company of the Year Award from the Life Science Association of Manitoba (LSAM). The Life Science Association of Manitoba represents the provinces biotechnology, pharmaceutical, medical device and health products industries.

The Sanford Project to Present Results of DiaMedica’s DM-199 for Type 1 Diabetes at the IDF World Diabetes Congress Conference

Posted by Anonymous on Sep, 27 2011

WINNIPEG, Manitoba – September 27, 2011 – DiaMedica (TSX-V:DMA) today announces that Dr. Alexi Savinov of The Sanford Project has been invited to present a poster based on its late-breaking abstract, detailing results of pre-clinical studies of DM-199 for the treatment of Type 1 diabetes. The material will be presented December 4-9, 2011 at the 21st biennial World Diabetes Congress organized by the International Diabetes Federation (IDF) in Dubai, United Arab Emirates.

DiaMedica Inc. Announces Results of Annual and Special General Meeting

Posted by Anonymous on Sep, 23 2011

WINNIPEG, Manitoba – September 23, 2011 – DiaMedica Inc. (“DiaMedica”) (TSX-V:DMA), a biotechnology company focused on diabetes, is pleased to announce that at the Annual and Special General Meeting (the “AGM”) of shareholders of DiaMedica dated September 22, 2011 David Allan, Michael Giuffre, Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas Wellner were elected as the board of directors of the Corporation.  

DiaMedica to Present Results of Monoclonal Antibody for Type 2 diabetes at the Biennial IDF World Diabetes Congress Conference

Posted by Anonymous on Sep, 19 2011

WINNIPEG, Manitoba – September 19, 2011 – DiaMedica (TSX-V:DMA) today announces that it has been invited to present its late-breaking abstract for a poster and presentation covering results of pre-clinical studies of DM-204 for the treatment of Type 2 diabetes. The material will be presented on December 5, 2011 at the 21st biennial World Diabetes Congress organized by the International Diabetes Federation (IDF) in Dubai, United Arab Emirates.

DiaMedica Expands Scientific Advisory Board with the Appointment of John M. Amatruda, M.D.

Posted by Anonymous on Aug, 3 2011

WINNIPEG, Manitoba – August 3, 2011 – DiaMedica Inc., (TSX-V:DMA), a biotechnology company focused on diabetes, announced today that John M. Amatruda, M.D. has joined the company’s Scientific Advisory Board (“SAB”), enhancing DiaMedica’s experienced advisory team.

DiaMedica Announces Completion of $3.88 Million Prospectus Offering

Posted by Anonymous on Jul, 22 2011

WINNIPEG, Manitoba - July 22, 2011 – DiaMedica Inc., (TSX-V:DMA), a biotechnology company focused on diabetes, is pleased to announce the completion today of its previously announced short form prospectus offering (the “Offering”).